Changes for page Customer segments in Health and Wellbeing Living Labs
Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.5
edited by Sarantis Dimitriadis
on 2022/06/02 10:48
on 2022/06/02 10:48
Change comment:
There is no comment for this version
To version 8.1
edited by Sarantis Dimitriadis
on 2023/05/30 10:01
on 2023/05/30 10:01
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -7,6 +7,8 @@ 7 7 (% class="western" lang="en-GB" style="text-align:justify" %) 8 8 (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following: 9 9 10 +: 11 + 10 10 * ((( 11 11 (% lang="en-US" %)**Non-professional end users:** 12 12 ... ... @@ -15,6 +15,8 @@ 15 15 * (% lang="en-US" %)**Public health and social service clients: **Those who use public services. 16 16 ))) 17 17 20 +: 21 + 18 18 * ((( 19 19 (% lang="en-US" %)**Professional end users** 20 20 ... ... @@ -25,9 +25,13 @@ 25 25 * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level. 26 26 ))) 27 27 32 +: 33 + 28 28 (% class="western" lang="en-GB" %) 29 29 (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows: 30 30 37 +: 38 + 31 31 * ((( 32 32 (% lang="en-US" %)**Private sector organizations: **(business developers and researchers) 33 33 ... ... @@ -42,6 +42,8 @@ 42 42 * (% lang="en-US" %)Pharmaceutical companies 43 43 ))) 44 44 53 +: 54 + 45 45 * ((( 46 46 (% lang="en-GB" %) 47 47 (% lang="en-US" %)**Public sector organizations:** ... ... @@ -57,6 +57,8 @@ 57 57 * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process. 58 58 ))) 59 59 70 +: 71 + 60 60 * ((( 61 61 (% lang="en-GB" %) 62 62 (% lang="en-US" %)**Education and research organizations:** ... ... @@ -70,6 +70,8 @@ 70 70 * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers 71 71 ))) 72 72 85 +: 86 + 73 73 * ((( 74 74 (% lang="en-GB" %) 75 75 (% lang="en-US" %)**Civil society organizations:** ... ... @@ -77,6 +77,8 @@ 77 77 * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level. 78 78 ))) 79 79 94 +: 95 + 80 80 * ((( 81 81 (% lang="en-GB" %) 82 82 (% lang="en-US" %)**Networks and clusters:** ... ... @@ -85,240 +85,89 @@ 85 85 * (% lang="en-US" %)International, national, regional and local networks 86 86 ))) 87 87 88 -(% class="western" lang="en-GB" %) 89 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table . 104 +: 90 90 91 -(% cellspacing="0" style="border-collapse:collapse; margin-left:auto; margin-right:auto" %) 92 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 93 -(% class="western" lang="en-GB" style="text-align:center" %) 94 -(% lang="en-US" %)**Age or age group** 95 -))) 96 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:11px; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 97 97 (% class="western" lang="en-GB" %) 107 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table . 108 + 109 +(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %) 110 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups** 111 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 98 98 (% lang="en-US" %)Specific age range 99 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 100 -(% class="western" %) 113 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 101 101 102 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)(((115 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 103 103 (% class="western" %) 104 104 105 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:152px" %)(((118 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 106 106 (% class="western" %) 107 107 108 108 ))) 109 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 110 -(% class="western" lang="en-GB" %) 111 -(% lang="en-US" %)Elderly 112 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 113 -(% class="western" lang="en-GB" %) 114 -(% lang="en-US" %)Adults 115 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 116 -(% class="western" lang="en-GB" %) 117 -(% lang="en-US" %)Youth 118 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:152px" %)((( 119 -(% class="western" lang="en-GB" %) 120 -(% lang="en-US" %)Children 121 -))) 122 -|(% colspan="4" style="border-bottom:none; border-left:none; border-right:none; border-top:none; height:12px; padding:0in; vertical-align:top; width:634px" %)((( 122 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population 123 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 123 123 (% class="western" %) 124 124 125 125 ))) 126 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 127 -(% class="western" lang="en-GB" style="text-align:center" %) 128 -(% lang="en-US" %)**Health status** 129 -))) 130 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 127 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)** 128 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 131 131 (% class="western" lang="en-GB" %) 132 132 (% lang="en-US" %)Healthy 133 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:justify; vertical-align:middle; width:153px" %)(((131 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 134 134 (% class="western" lang="en-GB" %) 135 - (%lang="en-US" %)Patient136 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:justify; vertical-align:middle; width:153px" %)(((133 + 134 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 137 137 (% class="western" lang="en-GB" %) 138 - (%lang="en-US" %)Rehabilitant139 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:justify; vertical-align:middle; width:152px" %)(((136 + 137 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 140 140 (% class="western" lang="en-GB" %) 141 - (%lang="en-US" %)Recovered/Survivor139 + 142 142 ))) 143 -|(% colspan="4" style="border- bottom:none; border-left:none; border-right:none; border-top:none; height:12px;padding:0in;vertical-align:top; width:634px" %)(((141 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 144 144 (% class="western" %) 145 145 146 146 ))) 147 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 148 -(% class="western" lang="en-GB" style="text-align:center" %) 149 -(% lang="en-US" %)**A specific disease, disorder or disability** 150 -))) 151 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 152 -(% class="western" lang="en-GB" %) 153 -(% lang="en-US" %)ADHD 154 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 155 -(% class="western" lang="en-GB" %) 156 -(% lang="en-US" %)Dementia 157 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 158 -(% class="western" lang="en-GB" %) 159 -(% lang="en-US" %)Parkinsons’ disease 160 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 161 -(% class="western" lang="en-GB" %) 162 -(% lang="en-US" %)Loneliness and Social Isolation 163 -))) 164 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:11px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 165 -(% class="western" lang="en-GB" %) 166 -(% lang="en-US" %)Autism 167 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 168 -(% class="western" lang="en-GB" %) 169 -(% lang="en-US" %)Down syndrome 170 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 171 -(% class="western" lang="en-GB" %) 172 -(% lang="en-US" %)Physical disability 173 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 174 -(% class="western" lang="en-GB" %) 175 -(% lang="en-US" %)Mental health 176 -))) 177 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 178 -(% class="western" lang="en-GB" %) 179 -(% lang="en-US" %)Cardiovascular disease 180 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 181 -(% class="western" lang="en-GB" %) 182 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF) 183 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 184 -(% class="western" lang="en-GB" %) 185 -(% lang="en-US" %)Sleep apnea/apnea 186 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 187 -(% class="western" lang="en-GB" %) 188 -(% lang="en-US" %)Mild cognitive impairment 189 -))) 190 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 191 -(% class="western" lang="en-GB" %) 192 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD) 193 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 194 -(% class="western" lang="en-GB" %) 195 -(% lang="en-US" %)Language disability 196 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 197 -(% class="western" lang="en-GB" %) 198 -(% lang="en-US" %)Substance abuse (drugs, alcohol) 199 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 200 -(% class="western" lang="en-GB" %) 201 -(% lang="en-US" %)Multiple sclerosis 202 -))) 203 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:50px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 204 -(% class="western" lang="en-GB" %) 205 -(% lang="en-US" %)Cognitive disorder (mild, major) 206 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 207 -(% class="western" lang="en-GB" %) 208 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation 209 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 210 -(% class="western" lang="en-GB" %) 211 -(% lang="en-US" %)Trauma patient 212 - 213 -(% class="western" lang="en-GB" %) 214 -(% lang="en-US" %)(e.g., a spinal cord injury) 215 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 216 -(% class="western" lang="en-GB" %) 217 -(% lang="en-US" %)Neurodegenerative diseases 218 -))) 219 -|(% colspan="4" style="border-bottom:none; border-left:none; border-right:none; border-top:none; height:12px; padding:0in; vertical-align:top; width:634px" %)((( 145 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)** 146 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Schizophrenia|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Parkinson Disease 147 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Post-Stroke Patients with Moving or Linguistic Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Mild Cognitive Impairment|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Sleep Disorders: e.g., Apnea, Hypopnea|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)With Disability 148 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy with Possible Chronic Conditions|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %) |(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %) |(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %) 149 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 220 220 (% class="western" %) 221 221 222 222 ))) 223 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 224 -(% class="western" lang="en-GB" style="text-align:center" %) 225 -(% lang="en-US" %)**Clients of a specific service** 226 -))) 227 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:11px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 228 -(% class="western" lang="en-GB" %) 229 -(% lang="en-US" %)Child welfare 230 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 231 -(% class="western" lang="en-GB" %) 232 -(% lang="en-US" %)Nursing home 233 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 234 -(% class="western" lang="en-GB" %) 235 -(% lang="en-US" %)Employment service 236 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 153 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)** 154 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy|(% style="border-color:currentcolor; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Parkinson Disease|(% style="border-color:currentcolor; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Mild Cognitive Impairment|(% style="border-color:currentcolor; height:30px; text-align:justify; vertical-align:middle; width:152px" %)With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 237 237 (% class="western" %) 238 238 239 239 ))) 240 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height: 12px;padding:0in; text-align:left; vertical-align:middle; width:153px" %)(((158 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy with Possible Chronic Conditions|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 241 241 (% class="western" lang="en-GB" %) 242 - (%lang="en-US" %)Early childhood education243 -)))|(% style="border- color:currentcolor; border-style:none; border-width:medium;padding:0in; text-align:left; vertical-align:middle; width:153px" %)(((160 + 161 +)))|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 244 244 (% class="western" lang="en-GB" %) 245 -(% lang="en-US" %)Home care 246 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 247 -(% class="western" lang="en-GB" %) 248 248 249 -)))|(% style="border- color:currentcolor; border-style:none; border-width:medium;padding:0in; text-align:left; vertical-align:middle; width:152px" %)(((164 +)))|(% style="border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 250 250 (% class="western" lang="en-GB" %) 251 251 252 252 ))) 253 -|(% colspan="4" style="border- bottom:none; border-left:none; border-right:none; border-top:none; height:12px;padding:0in;vertical-align:top; width:634px" %)(((168 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 254 254 (% class="western" %) 255 255 256 256 ))) 257 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 258 -(% class="western" lang="en-GB" style="text-align:center" %) 259 -(% lang="en-US" %)**Vulnerable groups** 260 -))) 261 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:50px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 172 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)** 173 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Healthy|(% style="text-align:justify; vertical-align:middle" %)Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 262 262 (% class="western" lang="en-GB" %) 263 -(% lang="en-US" %)Minors/Children 264 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 265 -(% class="western" lang="en-GB" %) 266 -(% lang="en-US" %)Single parents with minor children 267 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 268 -(% class="western" lang="en-GB" %) 269 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence 270 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 271 -(% class="western" lang="en-GB" %) 272 -(% lang="en-US" %)Substance users 273 - 274 -(% class="western" lang="en-GB" %) 275 -(% lang="en-US" %)(drugs, alcohol) 175 +Down Syndrome 276 276 ))) 277 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding: 0in; text-align:left; vertical-align:middle; width:153px" %)(((177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 278 278 (% class="western" lang="en-GB" %) 279 -(% lang="en-US" %)Disabled people 280 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 281 -(% class="western" lang="en-GB" %) 282 -(% lang="en-US" %)Victims of trafficking in human beings 283 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 284 -(% class="western" lang="en-GB" %) 285 -(% lang="en-US" %)Ethnic minorities and immigrants 286 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 287 -(% class="western" lang="en-GB" %) 288 -(% lang="en-US" %)Isolated people 289 -))) 290 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 291 -(% class="western" lang="en-GB" %) 292 -(% lang="en-US" %)Elderly people 293 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 294 -(% class="western" lang="en-GB" %) 295 -(% lang="en-US" %)Persons with serious illnesses 296 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 297 -(% class="western" lang="en-GB" %) 298 -(% lang="en-US" %)Homeless people 299 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 300 -(% class="western" lang="en-GB" %) 301 -(% lang="en-US" %)Ex-prisoners and people with criminal background 302 -))) 303 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 304 -(% class="western" lang="en-GB" %) 305 -(% lang="en-US" %)Pregnant women 306 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 307 -(% class="western" lang="en-GB" %) 308 -(% lang="en-US" %)Persons with mental disorders 309 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 310 -(% class="western" lang="en-GB" %) 311 311 312 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 313 -(% class="western" lang="en-GB" %) 314 - 315 315 ))) 316 316 182 +: 317 317 318 318 (% class="western" lang="en-GB" %) 319 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .185 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) . 320 320 321 - 322 322 |**Researcher expertise**|**Brief use case description** 323 323 |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making 324 324 |Experts in communication studies|Defining written, oral, visual and digital communication within a certain workplace. Evaluating (multi professional) healthcare team collaboration, communication and debriefing in various healthcare situations in simulated environments (especially in Simulation lab)